Current Headlines

  1. Gracell Announces China NMPA Acceptance Of Investigational New Drug Application For GC007g Cell Therapy For CD19 Positive Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia 4/3/2020

    Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell & gene therapy company, is pleased to announce that China National Medical Products Administration (NMPA) has accepted Gracell's Investigational New Drug (IND) application for GC007g, a donor-derived anti-CD19 chimeric antigen receptor (CAR-T) cell therapy

  2. Crown Bioscience Expands PDX Collection With Acquisition Of Unique Models From Leading Academic Medical Centers 4/2/2020

    Crown Bioscience today announced the strategic expansion of their PDX collection through new agreements with CoMotion at the University of Washington and Dana-Farber Cancer Institute

  3. Ennaid Therapeutics Announces Development Of ENU200, A New Antiviral Therapeutic For The Treatment Of COVID-19 4/2/2020

    Ennaid Therapeutics, LLC, a specialty pharmaceutical company that uses its artificial intelligence (AI)-based drug discovery platforms to develop antiviral drugs, today announced that it is advancing the development of ENU200, as a therapeutic to treat the up to 80% of asymptomatic, mild to moderate cases of COVID-19 viral infections

  4. Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19 4/2/2020

    Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies (NASDAQ:ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic

  5. Macromoltek Announces Computational De Novo Antibody Design Offering, Targeting COVID-19 4/1/2020

    Macromoltek, Inc. today announced computational de novo design capability to speed up the development of human monoclonal antibodies for the potential treatment of COVID-19

  6. AVEO Oncology Announces Submission Of New Drug Application To U.S. FDA For Tivozanib In Patients With Relapsed Or Refractory Renal Cell Carcinoma 3/31/2020

    AVEO Oncology today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tivozanib, the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma (RCC)

  7. Oxford BioTherapeutics (OBT) Announces Second Oncology Drug Candidate Selected To Advance Into Formal IND Enabling Studies From Boehringer Ingelheim (BI) Collaboration 3/31/2020

    Oxford BioTherapeutics Ltd. (“OBT”), a clinical stage oncology company with a pipeline of immuno-oncology and antibody drug conjugate-based therapies, today announced that Boehringer Ingelheim has selected a second asset to advance into formal IND enabling studies

  8. Lilly And Sitryx Announce Licensing And Research Collaboration To Discover And Develop New Immunometabolic Medicines 3/31/2020

    Eli Lilly and Company (NYSE: LLY) today announced an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation

  9. Coronavirus (COVID-19) Update: FDA Continues To Accelerate Development Of Novel Therapies For COVID-19 3/31/2020

    As part of the Trump Administration’s all-hands-on-deck approach across public, academic and private sectors to combat the COVID-19 pandemic, the U.S. Food and Drug Administration stood up a new program to expedite the development of potentially safe and effective life-saving treatments

  10. Evotec And Ildong To Collaborate With Development Projects On INDiGO Platform 3/31/2020

    Evotec SE announced today that the Company has entered into a strategic collaboration with Ildong Pharmaceutical Co., Ltd. (“Ildong”), a leading pharmaceutical company in South Korea, to accelerate the development of several of Ildong’s proprietary projects through access to Evotec’s INDiGO platform